These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 21590143)

  • 1. Combination chemoendocrine therapy containing vindesine for refractory metastatic breast cancer.
    Maemura M; Iino Y; Yokoe T; Takei H; Horiguchi J; Horii Y; Nagasawa M; Takeyoshi I; Ohwada S; Morishita Y
    Oncol Rep; 1997; 4(4):799-802. PubMed ID: 21590143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Combination chemotherapy using low-dose epirubicin and vindesine in patients with metastatic breast cancer].
    Takatsuka Y; Nakayama H; Kawahara T
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 1):667-71. PubMed ID: 2965547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Vindesine and adriamycin in the therapy of metastatic breast cancer].
    Wander HE; Nagel GA
    Onkologie; 1982 Aug; 5 Suppl():5-7. PubMed ID: 6752792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vindesine in the treatment of refractory breast cancer: improvement in therapeutic index with continuous 5-day infusion.
    Yap HY; Blumenschein GR; Bodey GP; Hortobagyi GN; Buzdar AU; DiStefano A
    Cancer Treat Rep; 1981; 65(9-10):775-9. PubMed ID: 7273012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of vindesine in patients with metastatic breast cancer.
    Cobleigh MA; Williams SD; Einhorn LH
    Cancer Treat Rep; 1981; 65(7-8):659-63. PubMed ID: 7248983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women.
    Klaassen DJ; Rapp EF; Hirte WE
    Cancer Treat Rep; 1976 Mar; 60(3):251-3. PubMed ID: 1260780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A case of disseminated breast cancer successfully treated with medroxyprogesterone acetate].
    Tsumura I; Okamura Y; Takatsuka Y; Kobayakawa K; Kawahara T
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1509-12. PubMed ID: 2143889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients.
    Zhang P; Tong Z; Tian F; Wang Y; Yang J; Li W; Di L; Liu W; Tang L; Qiu R; Xu B
    J Hematol Oncol; 2016 Aug; 9(1):68. PubMed ID: 27516093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Treatment Strategy for Bone Metastases from Breast Cancer.
    Kohno N; Kitazawa S; Konishi M; Wakita K; Furuya Y; Kawaguti K
    Breast Cancer; 1999 Oct; 6(4):292-297. PubMed ID: 11091732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of mitomycin C, 5'-deoxy-5-fluorouridine, etoposide and medroxyprogesterone acetate (McVD-MPA) as a salvage chemotherapy to anthracycline-resistant tumor in relapsed breast cancer and its mechanism(s) of antitumor action.
    Kim R; Osaki A; Tanabe K; Kojima J; Toge T
    Oncol Rep; 2001; 8(3):597-603. PubMed ID: 11295087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.
    Murthy R; Borges VF; Conlin A; Chaves J; Chamberlain M; Gray T; Vo A; Hamilton E
    Lancet Oncol; 2018 Jul; 19(7):880-888. PubMed ID: 29804905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vindesine-epirubicin versus vindesine-mitoxantrone in metastatic breast cancer.
    Hausmaninger H; Lehnert M; Steger G; Sevelda P; Michlmayr G; Hehenwarter W; Fridrik M; Samonigg H; Schiller L; Manfreda D
    Onkologie; 1989 Oct; 12(5):225-9. PubMed ID: 2685688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential administration of docetaxel followed by cisplatin-vindesine: a pilot study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
    Rixe O; Gatineau M; Jauffret E; Spano JP; Orcel B; Vannetzel JM; Berille J; Derenne JP; Khayat D
    Bull Cancer; 2005 Jan; 92(1):E1-6. PubMed ID: 15689321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Two cases of advanced breast cancer responding to oral chemoendocrine therapy with 5'-deoxy-5-fluorouridine, medroxyprogesterone acetate and cyclophosphamide (DMpC)].
    Kihara M; Kontani K; Yamauchi A; Yokomise H
    Gan To Kagaku Ryoho; 2005 May; 32(5):683-6. PubMed ID: 15918573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the activity and safety of weekly low-dose bevacizumab-based regimens in heavily pretreated patients with metastatic breast cancer.
    Zhai X; Hong R; Fan Y; Yuan P; Wang J; Sang D; Chen J; Zhao C; Ou K; Ma F; Xu B
    Thorac Cancer; 2018 May; 9(5):613-620. PubMed ID: 29575760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of adriamycin and dibromodulcitol in metastatic breast carcinoma.
    Tormey DC; Simon R; Falkson G; Bull J; Band P; Perlin E; Blom J
    Cancer Res; 1977 Feb; 37(2):529-34. PubMed ID: 832277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Alternative treatment with carmustine, vindesine and tamoxifen in previously cytostaticly (VAC, FMC) treated patients with metastatic breast cancer].
    Massner B; Voss I; Queisser W; Drings P; Fritze D; Westerhausen M
    Onkologie; 1982 Aug; 5 Suppl():46-51. PubMed ID: 6752791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of nedaplatin and vindesine for treatment of relapsed or refractory non-small-cell lung cancer.
    Takigawa N; Segawa Y; Ueoka H; Kiura K; Tabata M; Shibayama T; Takata I; Miyamoto H; Eguchi K; Harada M
    Cancer Chemother Pharmacol; 2000; 46(4):272-8. PubMed ID: 11052624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer.
    Hortobagyi GN; Heim W; Hutchins L; Rivera E; Mason B; Booser DJ; Kirshner J
    Cancer; 2010 Mar; 116(6):1440-5. PubMed ID: 20091835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Combination chemo-endocrine therapy of metastatic and stage IV breast cancer with cyclophosphamide, adriamycin, prednisolone and tamoxifen (CAPT)--with special reference to management of brain and liver metastasis].
    Nakamura Y; Kawaguchi M; Hata A; Watanabe H; Ueki Y; Oribe T; Koba F; Takamuku K
    Gan To Kagaku Ryoho; 1989 Feb; 16(2):243-50. PubMed ID: 2919892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.